Ishita Drugs & Industries Limited is the flagship company of ISHITA group. It is engaged in manufacture of various Active Pharma Ingredients, drug intermediates, fine chemicals and excipients.Product Portfolio: a) Active Pharma Ingredients: Sulfa Drugs / Sulfonamides, Vitamins, Fluoro Quinolones, Antibiotics, Anthelmintics, Iodides & Citrates (Salts), Food Additives / Excipients,...
Ishita Drugs & Industries has announced a board meeting to consider the financial results for the quarter and half-year. Their registrar and share transfer agent, Bigshare Services Pvt Ltd, confirmed all securities received for dematerialization have been verified, mutilated, cancelled, and updated in the register of members within 15 days,...
Ishita Drugs & Industries Ltd has announced a board meeting to consider the financial results for the quarter and half-year. Promoter Jagdish Agrawal acquired 1,630 shares of Rs.10 each through the open market, increasing his holding marginally from 4.28% to 4.29% of the total equity share capital of 29.9 million...
Ishita Drugs & Industries Ltd has announced a board meeting outcome where it approved the financial results for the quarter and year ended March 31, 2025, along with the Directors' Report, Corporate Governance Report, and related AGM notice. The board approved the re-appointment of internal auditors for FY 2025-26 and...
Ishita Drugs & Industries Ltd has confirmed that it did not raise any funds through public issue, rights issue, preferential issue, or QIP during the financial year ending March 31, 2025. Consequently, there are no deviations or variations in the utilization of issue proceeds to report. This confirms stable capital-raising...
Ishita Drugs & Industries Ltd has submitted a compliance certificate for the year ended March 31, 2025, confirming that no physical share transfer requests were received during the period. The company has issued all share certificates within the prescribed timeframe, except for those rejected on technical grounds. This update reflects...
